Clinicopathological characteristics and outcomes of gastrointestinal stromal tumors with high progranulin expression.
Jung, Kyung Uk
Sohn, Jin Hee
Son, Byung Ho
Lee, Sung Ryol
Shin, Jun Ho
Kim, Hyung Ook
Yoo, Chang Hak
PublisherPublic Library of Science
MetadataShow full item record
AbstractBackground & aims Progranulin (PGRN) is known to promote tumorigenesis and proliferation of several types of cancer cells. However, little is known about the clinicopathological features of patients with gastrointestinal stromal tumors (GISTs) with regard to PGRN expression. Methods A retrospective analysis was performed on patients with GISTs who underwent curative surgical resection between 2007 and 2017. PGRN expression was evaluated by immunohistochemical (IHC) analysis and semi-quantitatively categorized (no expression, 0; weak, 1+; moderate, 2+; strong, 3+). Tumors with a staining intensity of 2+ or 3+ were considered high PGRN expression. Results Fifty-four patients were analyzed; 31 patients (57%) were male. The median age at surgery was 60 years (range, 33–79), and the most common primary site was the stomach (67%). Thirty-five patients (65%) had spindle histology; 42 patients (78%) were separated as a high-risk group according to the modified National Institutes of Health (NIH) classification. High PGRN-expressing tumors were observed in 27 patients (50%), had more epithelioid/mixed histology (68% vs. 32%; p = 0.046), and KIT exon 11 mutations (76% vs. 24%; p = 0.037). Patients with high PGRN-expressing tumors had a worse recurrence-free survival (RFS) (36% of 5-year RFS) compared to those with low PGRN-expressing tumors (96%; p<0.001). Multivariate analysis showed that high PGRN expression and old age (>60 years) were independent prognostic factors for poor RFS. Conclusions High PGRN-expressing GISTs showed more epithelioid/mixed histology and KIT exon 11 mutations. PGRN overexpression was significantly associated with poor RFS in patients with GISTs who underwent curative resection.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/14358
- Prognostic Value of Progranulin in Patients with Colorectal Cancer Treated with Curative Resection.
- Authors: Koo DH, Do IG, Oh S, Lee YG, Kim K, Sohn JH, Park SK, Yang HJ, Jung YS, Park DI, Jeong KU, Kim HO, Kim H, Serrero G, Chun HK, KBSMC Colorectal Cancer Team.
- Issue date: 2020 Jan
- Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.
- Authors: Joensuu H, Wardelmann E, Sihto H, Eriksson M, Sundby Hall K, Reichardt A, Hartmann JT, Pink D, Cameron S, Hohenberger P, Al-Batran SE, Schlemmer M, Bauer S, Nilsson B, Kallio R, Junnila J, Vehtari A, Reichardt P
- Issue date: 2017 May 1
- Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors.
- Authors: Singer S, Rubin BP, Lux ML, Chen CJ, Demetri GD, Fletcher CD, Fletcher JA
- Issue date: 2002 Sep 15
- Progranulin as a predictive factor of response to chemotherapy in advanced biliary tract carcinoma.
- Authors: Kim JH, Do IG, Kim K, Sohn JH, Kim HJ, Jeon WK, Lee SR, Son BH, Shin JH, Nam H, Kwon HJ, Kim MS, Hong HP, Serrero G, Koo DH, KBSMC Pancreatobiliary Cancer Team.
- Issue date: 2016 Nov
- Differential expression of KIT/PDGFRA mutant isoforms in epithelioid and mixed variants of gastrointestinal stromal tumors depends predominantly on the tumor site.
- Authors: Wasag B, Debiec-Rychter M, Pauwels P, Stul M, Vranckx H, Oosterom AV, Hagemeijer A, Sciot R
- Issue date: 2004 Aug